COVID-19 Community Levels Map Update, August 12, 2022: The Centers for Disease Control and Prevention has listed New Haven, Fairfield, Litchfield, New London and Middlesex Counties in the Medium/Yellow category as part of its COVID-19 Community Levels Map. Hartford, Tolland, and Windham Counties are listed in the Low/Green category. Visit the CDC COVID-19 Community Levels Map for updates.

Monkeypox: Please visit our monkeypox webpage for the latest updates.

| CTR Home | Data & Statistics | Research | Resources for Registrars | Reporting RequirementsOther Resources | Contact CTR



Health care providers, clinical laboratories, and hospitals are required by Connecticut statute (Chapter 368a, Section 19a-72) to report all cases of malignant tumors (and associated conditions) to CTR.  Timelines for reporting and civil penalties associated with failure to report are described in the statute.  Facility reporting to CTR does not violate HIPAA regulations.





Q:  What are the changes to reportability applicable to cases diagnosed in 2018 and forward? 
A:  The following links provide specific information on 2018 updates to reporting requirements: 

            Updated 2018 Guidelines (.pdf)
Updated 2018 ICD-O-3 Numeric Table (.pdf)
Updated 2018 ICD-O-3 Table (.xlsx)
ICD-O-3 Table Errata (.pdf)


Q:  Which cancer cases and data must be reported? 
A:  The following links detail specific cancer reporting requirements: 

            Reportable List (2018-2019)  (PDF, 65KB)

            Reportable List (2016)  (PDF, 65KB)

            Casefinding List (PDF, 159KB)

            NAACCR Required Data Items (PDF, 138KB) 


Q: What options are available for submitting reports to CTR? 
A: Facilities can report either electronically or via hard copy.
Contact CTR for more information.


Reporting Forms

            Patient Reporting Form (PDF, 62KB)



Have further questions about reporting?  Please contact CTR's Registrar of Tumor Records.



Useful reporting links:



For more information, please contact CTR at (860) 509-7163.



This work has been supported by federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800002I.